These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 34341098

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC, Krysa JA, Chaker S, Abujrad H, Mayne J, Henry K, Cousins M, Raymond A, Favreau C, Taljaard M, Chrétien M, Mbikay M, Proctor SD, Vine DF.
    J Clin Endocrinol Metab; 2017 Sep 01; 102(9):3452-3460. PubMed ID: 28673045
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
    Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL.
    JAMA; 2019 Jan 29; 321(4):364-373. PubMed ID: 30694319
    [Abstract] [Full Text] [Related]

  • 6. Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease.
    Peloso GM, Nomura A, Khera AV, Chaffin M, Won HH, Ardissino D, Danesh J, Schunkert H, Wilson JG, Samani N, Erdmann J, McPherson R, Watkins H, Saleheen D, McCarthy S, Teslovich TM, Leader JB, Lester Kirchner H, Marrugat J, Nohara A, Kawashiri MA, Tada H, Dewey FE, Carey DJ, Baras A, Kathiresan S.
    Circ Genom Precis Med; 2019 May 29; 12(5):e002376. PubMed ID: 30939045
    [Abstract] [Full Text] [Related]

  • 7. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
    Humphries SE, Neely RD, Whittall RA, Troutt JS, Konrad RJ, Scartezini M, Li KW, Cooper JA, Acharya J, Neil A.
    Clin Chem; 2009 Dec 29; 55(12):2153-61. PubMed ID: 19797716
    [Abstract] [Full Text] [Related]

  • 8. PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.
    Kent ST, Rosenson RS, Avery CL, Chen YI, Correa A, Cummings SR, Cupples LA, Cushman M, Evans DS, Gudnason V, Harris TB, Howard G, Irvin MR, Judd SE, Jukema JW, Lange L, Levitan EB, Li X, Liu Y, Post WS, Postmus I, Psaty BM, Rotter JI, Safford MM, Sitlani CM, Smith AV, Stewart JD, Trompet S, Sun F, Vasan RS, Woolley JM, Whitsel EA, Wiggins KL, Wilson JG, Muntner P.
    Circ Cardiovasc Genet; 2017 Aug 29; 10(4):e001632. PubMed ID: 28768753
    [Abstract] [Full Text] [Related]

  • 9. Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.
    Vilar-Gomez E, Gawrieh S, Liang T, McIntyre AD, Hegele RA, Chalasani N.
    J Clin Lipidol; 2021 Aug 29; 15(2):275-291. PubMed ID: 33454241
    [Abstract] [Full Text] [Related]

  • 10. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
    Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH, Humphries SE.
    Clin Sci (Lond); 2007 Dec 29; 113(11):435-41. PubMed ID: 17550346
    [Abstract] [Full Text] [Related]

  • 11. R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
    Mostaza JM, Lahoz C, Salinero-Fort MA, de Dios O, Castillo E, González-Alegre T, García-Iglesias F, Estirado E, Laguna F, Sabín C, López S, Cornejo V, de Burgos C, Sanchez V, Garcés C, investigators of the SPREDIA-2 Group.
    J Clin Lipidol; 2018 Dec 29; 12(4):1039-1046.e3. PubMed ID: 29773421
    [Abstract] [Full Text] [Related]

  • 12. Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis.
    Pott J, Kheirkhah A, Gadin JR, Kleber ME, Delgado GE, Kirsten H, Forer L, Hauck SM, Burkhardt R, Scharnagl H, Loeffler M, März W, Thiery J, Gieger C, Peters A, Silveira A, Hooft FV, Kronenberg F, Scholz M.
    Biol Sex Differ; 2024 Mar 26; 15(1):26. PubMed ID: 38532495
    [Abstract] [Full Text] [Related]

  • 13. Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.
    Lee CJ, Lee Y, Park S, Kang SM, Jang Y, Lee JH, Lee SH.
    PLoS One; 2017 Mar 26; 12(10):e0186446. PubMed ID: 29036232
    [Abstract] [Full Text] [Related]

  • 14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 26; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 15. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR.
    J Clin Endocrinol Metab; 2016 Sep 26; 101(9):3281-7. PubMed ID: 27218270
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM, Dorsch MP, Bleske BE.
    Pharmacotherapy; 2013 Apr 26; 33(4):447-60. PubMed ID: 23553812
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
    Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, Collins R, METASTROKE Collaboration of the ISGC.
    Eur Heart J; 2018 Feb 01; 39(5):354-359. PubMed ID: 29020353
    [Abstract] [Full Text] [Related]

  • 18. Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations.
    Hayat M, Kerr R, Bentley AR, Rotimi CN, Raal FJ, Ramsay M.
    PLoS One; 2020 Feb 01; 15(2):e0229098. PubMed ID: 32084179
    [Abstract] [Full Text] [Related]

  • 19. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
    Huijgen R, Blom DJ, Hartgers ML, Chemello K, Benito-Vicente A, Uribe KB, Behardien Z, Blackhurst DM, Brice BC, Defesche JC, de Jong AG, Jooste RJ, Solomon GAE, Wolmarans KH, Hovingh GK, Martin C, Lambert G, Marais AD.
    Arterioscler Thromb Vasc Biol; 2021 Feb 01; 41(2):934-943. PubMed ID: 33147992
    [Abstract] [Full Text] [Related]

  • 20. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS.
    J Am Coll Cardiol; 2014 Feb 11; 63(5):430-3. PubMed ID: 24161333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.